Taysha Gene Therapies (NASDAQ:TSHA) Rating Reiterated by Needham & Company LLC

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a report issued on Thursday, Benzinga reports. They currently have a $7.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 172.37% from the company’s current price.

Several other equities research analysts also recently commented on the company. Piper Sandler started coverage on Taysha Gene Therapies in a report on Tuesday, April 9th. They set an “overweight” rating and a $9.00 price objective for the company. Chardan Capital boosted their price objective on Taysha Gene Therapies from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, March 21st. Canaccord Genuity Group restated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $6.88.

Taysha Gene Therapies Trading Up 6.2 %

TSHA stock traded up $0.15 during mid-day trading on Thursday, reaching $2.57. The company’s stock had a trading volume of 1,065,447 shares, compared to its average volume of 2,514,342. The company has a market cap of $480.64 million, a price-to-earnings ratio of -3.84 and a beta of 0.37. The business’s 50 day moving average price is $2.65 and its 200 day moving average price is $2.09. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.54. Taysha Gene Therapies has a 12 month low of $0.50 and a 12 month high of $3.89.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, March 19th. The company reported $0.35 EPS for the quarter. The firm had revenue of $3.60 million for the quarter, compared to the consensus estimate of $4.75 million. On average, equities research analysts predict that Taysha Gene Therapies will post -0.39 EPS for the current year.

Institutional Trading of Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC raised its stake in shares of Taysha Gene Therapies by 44.0% during the 3rd quarter. Commonwealth Equity Services LLC now owns 26,971 shares of the company’s stock valued at $85,000 after purchasing an additional 8,246 shares during the period. Kovitz Investment Group Partners LLC increased its stake in Taysha Gene Therapies by 66.7% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 25,000 shares of the company’s stock worth $79,000 after acquiring an additional 10,000 shares during the last quarter. Howard Capital Management Inc. bought a new position in Taysha Gene Therapies in the 4th quarter worth about $25,000. China Universal Asset Management Co. Ltd. increased its stake in Taysha Gene Therapies by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company’s stock worth $103,000 after acquiring an additional 14,286 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new position in Taysha Gene Therapies in the 4th quarter worth about $28,000. 77.70% of the stock is currently owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.